Stage I–II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy

Abstract

We set to identify prognostic factors in a retrospective cohort of consecutive patients with stage I-II diffuse large B-cell lymphoma treated with rituximab-chemotherapy with or without radiotherapy from 2001 through 2017 at our institution. We identified 143 patients with median follow-up of 7.7 years. The majority were male (59.4%), had stage II (53.1%), had stage-modified IPI 0–1 (smIPI, 58.1%), and had non-bulky disease (<7 cm, 68.5%). 99 patients (69.2%) received rituximab-chemotherapy followed by radiotherapy, and 44 patients (30.8%) received rituximab-chemotherapy alone. The 5-year progression-free survival (PFS) and overall survival (OS) were 81.2% and 88.9%, respectively. The 5-year PFS for those with smIPI 0–1 versus 2–4 was 89.5% versus 69.7%, respectively (P = 0.005). Bulky disease (≥7 cm) was associated with worse PFS and OS on univariable and multivariable analyses (P < 0.05). Patients with smIPI 0–1 without bulky disease have excellent outcomes. However, patients with smIPI 2–4 or bulky disease have a high risk of progression.

Keywords:

• Early stage
• diffuse large B-cell lymphoma
• radiation
• lymphoma and Hodgkin disease
• cytogenetics
• chemotherapeutic approaches

Disclosure statement

No potential conflict of interest was reported by the author(s).